Brivaracetam Dosage Adjustment for Breakthrough Focal Seizures
For a patient experiencing breakthrough focal seizures on Brivaracetam 150 mg twice daily, increase the dose to 200 mg per day (100 mg twice daily), which is the maximum recommended dose. 1
Dosage Titration Strategy
The FDA-approved dosing for Brivaracetam allows for adjustment based on individual tolerability and therapeutic response:
- Current dose: 150 mg BID (300 mg/day total)
- Maximum approved dose: 100 mg BID (200 mg/day total) 1
Your patient is already above the maximum recommended dose. The FDA label clearly states that based on tolerability and therapeutic response, dosage may be adjusted down to 25 mg twice daily (50 mg/day) or up to 100 mg twice daily (200 mg/day) 1. Your patient at 150 mg BID is receiving 300 mg/day, which exceeds this maximum.
Recommended Action
Reduce the dose to 100 mg twice daily (200 mg/day) and reassess seizure control. If seizures persist at the maximum approved dose of 200 mg/day, consider:
- Adding or switching to an alternative antiseizure medication
- Investigating potential drug interactions that may be reducing Brivaracetam efficacy
- Evaluating medication adherence and seizure triggers
Therapeutic Drug Monitoring
Routine serum level monitoring of Brivaracetam is NOT required or recommended. 1
The FDA label explicitly states that blood levels of Brivaracetam were measured in clinical trials, but no therapeutic range was identified 2. Unlike older antiseizure medications such as phenytoin, carbamazepine, or valproic acid, Brivaracetam does not require therapeutic drug monitoring because:
- It exhibits linear and time-independent pharmacokinetics at approved doses 1
- Less than 10% is excreted unchanged in urine 1
- Dosing is based on clinical response and tolerability, not serum concentrations
When to Consider Drug Level Assessment
While routine monitoring is unnecessary, consider checking Brivaracetam levels in specific circumstances:
- Suspected non-adherence to medication regimen
- Drug-drug interactions with enzyme inducers (rifampin, carbamazepine, phenytoin, phenobarbital) that decrease Brivaracetam exposure by 19-26% 3
- Addition of CYP2C19 inhibitors (like cenobamate) that can increase Brivaracetam levels by approximately 27% 4
- Unexplained toxicity or adverse effects
Important Drug Interactions to Consider
Several medications can affect Brivaracetam concentrations:
Enzyme inducers that DECREASE Brivaracetam levels:
- Rifampin: 26% reduction 3
- Carbamazepine: 26% reduction 3
- Phenytoin: 21% reduction 3
- Phenobarbital: 19% reduction 3
If your patient is on any of these medications, the breakthrough seizures may be due to reduced Brivaracetam exposure rather than inadequate dosing.
CYP2C19 inhibitors that INCREASE Brivaracetam levels:
- Cenobamate can increase Brivaracetam by 27% 4
Clinical Efficacy Data
Phase III trials demonstrated that maximum therapeutic response occurs at 150-200 mg/day 3. The responder rate (≥50% seizure reduction) was:
- 48.89% with Brivaracetam 200 mg/day vs 23.86% with placebo 5
- Seizure freedom achieved in 11.11% of patients on Brivaracetam vs 2.27% on placebo 5
Common Pitfalls
Exceeding maximum approved dose: Your patient is already above the 200 mg/day maximum. Higher doses have not been shown to provide additional benefit and may increase adverse effects.
Co-administration with levetiracetam: If your patient is also taking levetiracetam, Brivaracetam provides no added therapeutic benefit 1. In fact, levetiracetam co-administration reduces the fraction of responders to only 4% 3. Consider discontinuing levetiracetam if both are being used.
Ignoring drug interactions: Check for enzyme-inducing antiseizure medications that may be reducing Brivaracetam efficacy.
Premature dose escalation: Ensure adequate trial duration (at least 12 weeks at current dose) before declaring treatment failure 6.